Dr. Workeneh, a double Board-certified nephrologist and internist, and professor will discuss the pathophysiology and management of HTN in patients with ADPKD, CKD, and the GP.
User experience form

Attend live and virtual events that provide a platform for education and collaborative discussion about the management of kidney disease and strategies to improve kidney health.
Any NephU member can request a presentation for their region or organization at no charge.
|
S
Sun
|
M
Mon
|
T
Tue
|
W
Wed
|
T
Thu
|
F
Fri
|
S
Sat
|
|---|---|---|---|---|---|---|
|
0 events,
|
0 events,
|
1 event,
to
Dr. Workeneh, a double Board-certified nephrologist and internist, and professor will discuss the pathophysiology and management of HTN in patients with ADPKD, CKD, and the GP. |
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
0 events,
|
|
0 events,
|
0 events,
|
1 event,
to
Autosomal Dominant Polycystic Kidney Disease (ADPKD), an inherited progressive kidney disease, is the fourth leading cause of kidney failure in the US. ADPKD has a spectrum of clinical and imaging features that have direct prognostic implications1. Total kidney volume (TKV), adjusted for height and age, has been shown to be the best predictor of kidney function decline; this forms the basis for the Mayo Clinic Imaging Classification (MCIC) of the severity grade of ADPKD1. Radiology’s central role in ADPKD is to aid in the imaging-based diagnosis, prognostication, and monitoring for disease progression. |
0 events,
|
0 events,
|
0 events,
|
0 events,
|